Lymphoma: all 5,624 studies
Page 39 of 57. Open to participants first (824), then studies with results posted, then the rest; newest registration first within each.
- Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin LymphomaTerminatedNCT01900496Phase 1
- Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell LymphomasCompletedNCT01897012Phase 1
- Dual Time Point PET in LymphomaStatus unknownNCT01894945
- Acupuncture for Chemotherapy-induced Peripheral NeuropathyStatus unknownNCT01892852Not applicable
- Evaluation of Immunological Reconstitution After Haploidentical Bone Marrow TransplantationStatus unknownNCT01891578
- Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT01886859Phase 1
- Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma PatientsStatus unknownNCT01884441Phase 2
- Study of Combination of PIGEV Before Autologous Stem Cell Transplant in Patients With Hodgkin's LymphomaStatus unknownNCT01884428Phase 1
- A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell LymphomaTerminatedNCT01878708Early Phase 1
- Samsung Medical Center-Lymphoma Cohort Study-IICompletedNCT01877109
- A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's LymphomaCompletedNCT01877005Phase 2
- Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic MalignanciesCompletedNCT01871675Phase 1
- Music & Cancer - Live Music During ChemotherapyCompletedNCT01870479Not applicable
- R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCLCompletedNCT01865110Phase 3
- The Use of PET for the Early Response Evaluation in Patients With Diffuse Large B-cell Lymphoma.Status unknownNCT01865058
- Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19Status unknownNCT01864889Not applicable
- Treatment for Advanced B-Cell LymphomaCompletedNCT01859819Phase 2
- Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12ACompletedNCT01858922Phase 2
- Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell LymphomaCompletedNCT01854606Phase 1
- Rituximab-HyperCVAD (R-HCVAD) Alternating With Rituximab-Methotrexate-Cytarabine- (R-MC) in Newly Diagnosed Patients With Diffuse Large B-Cell Lymphoma With MYC-Rearrangement.WithdrawnNCT01854372Phase 2
- Helical Irradiation of Total Skin (HITS) for T Cell LymphomaStatus unknownNCT01854112
- R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3BStatus unknownNCT01852435Phase 3
- Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHLCompletedNCT01851551Phase 1/2
- Phase II Study Evaluating a Combination of Pegylated Liposomal Doxorubicin and Dexamethasone for the Treatment of Immunocompetent Patients With Cerebral Lymphoma Relapsed or Refractory to First-line Chemotherapy With High Dose Methotrexate (MTXHD) and / or High-dose Cytarabine.TerminatedNCT01848652Phase 2
- Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.CompletedNCT01848132Phase 2
- Therapeutic Efficacy of Topical Sirolimus in Early Stage Cutaneous T-cell Lymphoma (CTCL)WithdrawnNCT01843998Phase 2
- Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOPWithdrawnNCT01843868Not applicable
- Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute LeukemiaCompletedNCT01842672Phase 1/2
- Evolution of Bone Mineral Density (BMD) in Patients With Lymphoma Undergoing ChemotherapyWithdrawnNCT01841814Phase 4
- Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)CompletedNCT01839097Phase 1
- Kinetic of Cytokines Decrease and Hodgkin Lymphoma PrognosticCompletedNCT01833884Not applicable
- An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell LymphomaApproved for marketingNCT01833039
- Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy AgentsCompletedNCT01831505Phase 1
- Lenalidomide Plus Rituximab (R) in Non Follicular NHLStatus unknownNCT01830478Phase 2
- VELCADE® Plus Rituximab in Non Hodgkin's Follicular LymphomaCompletedNCT01830465Phase 2
- Treatment of CD20 Antibody Plus CIK for Patients With Refractory LymphomasStatus unknownNCT01828008
- Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell TransplantCompletedNCT01822509Phase 1
- Brain Integrity in Survivors of Hodgkin Lymphoma Treated With Thoracic RadiationCompletedNCT01820117
- Hyper-CVAD Treatment in Lymphoblastic LymphomaStatus unknownNCT01813344
- Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin LymphomaStatus unknownNCT01811368Phase 2
- Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in AdultsCompletedNCT01809600
- CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell LymphomaCompletedNCT01806337Phase 2
- Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.CompletedNCT01805557Phase 2/3
- CD5789 in Early Cutaneous T-Cell Lymphoma (CTCL)CompletedNCT01804335Phase 1
- Interim PET/CT Guided Cycle Numbers of R-CHOP in DLBCLStatus unknownNCT01804127Phase 2
- Phase1 Study of Gemcitabine HCl Oral Formulation(D07001-F4) in Patients With Advanced Solid Malignancies and Malignant LymphomasCompletedNCT01800630Phase 1
- Lower Dose Decitabine Based Therapy in Patients With Refractory and/or Chemotherapy Resistant Solid Tumors or B Cell LymphomasStatus unknownNCT01799083Phase 1/2
- Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell LymphomaCompletedNCT01796002Phase 3
- Indenoisoquinoline LMP400 for Advanced Solid Tumors and LymphomasCompletedNCT01794104Phase 1
- A Study of Improving the Efficacy of Treatment in Diffused Large B Cell Lymphoma PatientsStatus unknownNCT01793844
- Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed LymphomasCompletedNCT01793233
- Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving FolotynWithdrawnNCT01789723Phase 1
- p-AKT Expression on Clinical Outcomes in Malignant LymphomaCompletedNCT01789060
- Lenalidomide, MTX, Ara-C and Rituximab in Relapsed Aggressive B-cell LymphomasCompletedNCT01788189Phase 1/2
- A Study of Improving the Efficacy of Treatment in High Risk T Cell Lymphoma PatientsStatus unknownNCT01788137Phase 3
- A Safety Study of SGN-CD19A for B-Cell LymphomaCompletedNCT01786135Phase 1
- A Safety Study of SGN-CD19A for Leukemia and LymphomaCompletedNCT01786096Phase 1
- Thiotepa, Busulfan and Fludarabin for pt With Refractory/Early Relapsed Aggressive B-cell Non Hodgkin LymphomasStatus unknownNCT01786018Phase 2
- A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular LymphomaCompletedNCT01779791Phase 2
- Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin LymphomaWithdrawnNCT01769911Not applicable
- Recombinant Human IL-18 and Ofatumumab After PBSCT for LymphomaCompletedNCT01768338Phase 1
- Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based ImmunochemotherapyStatus unknownNCT01768195Phase 4
- Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic MalignanciesCompletedNCT01767766Phase 1
- Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous TransplantationCompletedNCT01767714Phase 3
- A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell LymphomaCompletedNCT01766583Phase 1
- Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With LymphomaStatus unknownNCT01765231Phase 4
- Prevention of Ovarian Function Damage by a GnRH Analogue During Chemotherapy in Hodgkin Lymphoma PatientsCompletedNCT01764230Not applicable
- Improve the Survival Rate of Chinese Children and Adolescents With Non-Hodgkin's LymphomaCompletedNCT01761500Phase 2
- Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)WithdrawnNCT01754870Phase 2
- MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or LymphomaCompletedNCT01748721Phase 1
- CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell LymphomaStatus unknownNCT01746992Phase 4
- Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT)TerminatedNCT01745354Phase 1
- Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid MalignanciesTerminatedNCT01744912Phase 1
- Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT01744626Phase 1
- Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With LymphomaCompletedNCT01742988Phase 1
- An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)TerminatedNCT01742793Phase 1
- Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCLCompletedNCT01737177Phase 2
- Temozolomide, Nedaplatin, Vincristine, and Radiotherapy as First-line Treatment in Newly Diagnosed Primary CNS LymphomaStatus unknownNCT01735747Phase 2
- Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to ChemotherapyStatus unknownNCT01735604Phase 1/2
- Optical Detection of Peripheral Nerve Bundles During SurgeryCompletedNCT01731379
- Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell LymphomaCompletedNCT01729806Phase 1
- Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell LymphomaTerminatedNCT01729104Phase 1
- Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLLTerminatedNCT01728207Phase 1
- An Observational Study of MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in First-Line in Patients With Diffuse Large B-Cell LymphomaTerminatedNCT01724294
- Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular LymphomaCompletedNCT01722305Phase 1
- CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II StudyStatus unknownNCT01719835Phase 2
- Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT01719250Early Phase 1
- Prospective Study of Lymphoproliferative DiseasesWithdrawnNCT01704742
- A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or LymphomaCompletedNCT01703481Phase 1
- Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin's LymphomaCompletedNCT01701232Phase 3
- Assessment of Impact Nutritional Program During Autologous Stem Cell TransplantTerminatedNCT01699581Phase 2
- Phase 1 Study of TG02 Citrate in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaCompletedNCT01699152Phase 1
- A Phase I Study: PET Imaging of Cancer Patients Using [18F] 4-L-Fluoroglutamine (2S,4R)Active, not recruitingNCT01697930Phase 1
- Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's LymphomaCompletedNCT01691807Phase 1
- A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in KoreaCompletedNCT01689220Phase 1
- Rituximab and Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients With Aggressive B-cell LymphomaCompletedNCT01686321Phase 2
- An Observational Study of First-Line Maintenance Rituximab (MabThera/Rituxan) in Participants With Follicular Non-Hodgkin's LymphomaCompletedNCT01684865
- A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaCompletedNCT01682616Phase 1
- Intensive Chemo-immunotherapy as First Line Treatment in Adult Patients With Peripheral T- Cell LymphomaCompletedNCT01679860Phase 2
- 131I-rituximab for Relapsed or Refractory Follicular or Mantle Cell LymphomaStatus unknownNCT01678417Phase 2